无对比剂心脏磁共振风险评分用于再灌注ST段抬高型心肌梗死长期风险分层
本研究在推导队列(370例)和验证队列(234例)中比较无对比剂心脏磁共振风险评分与GRACE评分对再灌注STEMI患者1年复合终点(全因死亡、非致死性心肌梗死、新发充血性心力衰竭)的预测价值。3种评分在推导队列中预测效能相似且优于GRACE评分(C统计量0.83、0.83、0.82 vs 0.74);评分3在验证队列中区分度和校准度良好(C统计量0.87,Hosmer-Lemeshow检验P=0.71)。5年复合终点Kaplan-Meier分析显示,LVEF≤45%高危组和LVEF>45%且存在IMH中危组的累积事件显著高于LVEF>45%且无IMH低危组。
要点
- 无对比剂CMR风险评分(LVEF≤45%、IMH及GRACE评分)在验证队列中预测1年复合终点C统计量为0.87。
- LVEF≤45%为高危组,LVEF>45%且存在IMH为中危组,LVEF>45%且无IMH为低危组。
- 高危组HR为2.3(95%CI:1.1-4.7),中危组HR为2.0(95%CI:1.0-3.8),校正GRACE评分后仍显著。
核心结论
- 无对比剂CMR风险评分预测效能与既有风险评分相当,可将STEMI患者分为低危(LVEF>45%且无IMH)、中危(LVEF>45%且存在IMH)和高危(LVEF≤45%)三层。
研究设计与样本
- 研究论文,推导队列370例、验证队列234例;采用Eitel CMR风险评分和GRACE评分作为参照,定义评分1(急性MI面积≥19% LV、LVEF≤47%、MVO>1.4% LV及GRACE评分)、评分2(以IMH替代MVO)、评分3(仅LVEF≤45%、IMH及GRACE评分)。
关键影像表现/征象
- CMR可评估左心室射血分数(LVEF)、心肌梗死面积、微血管阻塞(MVO)及心肌内出血(IMH)。
- 评分3包含LVEF≤45%、IMH及GRACE评分,不依赖对比剂。
诊断标准与关键数值
- 评分1:急性MI面积≥19% LV、LVEF≤47%、MVO>1.4% LV及GRACE评分。
- 评分2:急性MI面积≥19% LV、LVEF≤47%、IMH及GRACE评分。
- 评分3:LVEF≤45%、IMH及GRACE评分。
- 推导队列1年复合终点C统计量:评分1为0.83、评分2为0.83、评分3为0.82、GRACE评分为0.74。
- 验证队列评分3的1年复合终点C统计量为0.87,Hosmer-Lemeshow拟合优度检验P=0.71。
临床应用与阅片要点
- 无对比剂CMR风险评分可用于再灌注STEMI患者的长期风险分层,分层依据为LVEF和IMH。
- 评分3仅需LVEF≤45%、IMH及GRACE评分,在验证队列中区分度和校准度良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study compared the prognostic value of a noncontrast CMR risk score for the composite of all-cause death, nonfatal myocardial infarction, and new congestive heart failure.
BACKGROUND: A cardiovascular magnetic resonance (CMR) risk score including left ventricular ejection fraction (LVEF), myocardial infarct (MI) size, and microvascular obstruction (MVO) was recently proposed to risk-stratify patients with ST-segment elevation myocardial infarction (STEMI).
METHODS: The Eitel CMR risk score and GRACE (Global Registry of Acute Coronary Events) score were used as a reference (Score 1: acute MI size ≥19% LV, LVEF ≤47%, MVO >1.4% LV and GRACE score). MVO was replaced by intramyocardial hemorrhage (IMH) in Score 2 (acute MI size ≥19% LV, LVEF ≤47%, IMH, and GRACE score). Score 3 included only LVEF ≤45%, IMH, and GRACE score.
RESULTS: There were 370 patients in the derivation cohort and 234 patients in the validation cohort. In the derivation cohort, the 3 scores performed similarly and better than GRACE score to predict the 1-year composite endpoint with C-statistics of 0.83, 0.83, 0.82, and 0.74, respectively. In the validation cohort, there was good discrimination and calibration of score 3, with a C-statistic of 0.87 and P = 0.71 in a Hosmer-Lemeshow test for goodness of fit, on the 1-year composite outcome. Kaplan-Meier curves for 5-year composite outcome showed that those with LVEF ≤45% (high-risk) and LVEF >45% and IMH (intermediate-risk) had significantly higher cumulative events than those with LVEF >45% and no IMH (low-risk), log-rank tests: P = 0.02 and P = 0.03, respectively. The HR for the high-risk group was 2.3 (95% CI: 1.1-4.7) and for the intermediate-risk group was 2.0 (95% CI: 1.0-3.8), and these remained significant after adjusting for the GRACE score.
CONCLUSIONS: This noncontrast CMR risk score has performance comparable to an established risk score, and patients with STEMI could be stratified into low risk (LVEF >45% and no IMH), intermediate risk (LVEF >45% and IMH), and high risk (LVEF ≤45%). (A Trial of Low-dose Adjunctive alTeplase During prIMary PCI [T-TIME]; NCT02257294) (Detection and Significance of Heart Injury in ST Elevation Myocardial Infarction [BHF MR-MI]; NCT02072850).
引用
- Bulluck, Carberry, Carrick, et al. A Noncontrast CMR Risk Score for Long-Term Risk Stratification in Reperfused ST-Segment Elevation Myocardial Infarction. JACC Cardiovasc Imaging. 2022. PMID: 35272808. doi:10.1016/j.jcmg.2021.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。